Start Date
February 28, 2009
Primary Completion Date
February 28, 2010
Study Completion Date
February 28, 2011
doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate
doxorubicin 20mg/m2 weekly x 12 wks, cyclophosphamide 50 mg PO qd x 12 wks, methotrexate 2.5 mg PO bid d1,2 wkly x 12. One week later paclitaxel poliglumex 135mg/m2 IV every 3 wks plus capecitabine 825 mg/m2 PO bid x 14days x 4 cycles
USC/Norris Comprehensive Cancer Center, Los Angeles
Collaborators (1)
CTI BioPharma
INDUSTRY
University of Southern California
OTHER